Cue Biopharma (CUE : NASDAQ)
Common Stock
Follow CUE
CUE
Cue Biopharma
Performance
1 Day
+68.20%
1 Week
-74.49%
1 Month
-70.40%
YTD
-82.19%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$102.43M
52W High
$45.50
52W Low
$4.97
P/E Ratio
-
50 Day MA
$23.94
200 Day MA
$21.57
Beta
2.81
Dividend Yield
-
Performance history
CUE returns since 2026
Cue Biopharma has traded since Jun 2026 in our data. Its deepest fall was −92.5% (Sep 2026 to Nov 2026).
1 year / yr
—
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2026*−82.2%
* Partial year (first year of data, or year to date).
$10,000 invested in CUE
- 2026 (start of our data)$1,781
- All-time high in our data
- $38 on Sep 17, 2026 · now −87.4%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Jun 2026 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past CUE? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/18/2026 | $3.41 | $4.77 | $3.27 | $4.76 | $4.76 | 13,229,241 |
| 11/17/2026 | $13.02 | $13.52 | $2.83 | $2.83 | $2.83 | 4,229,479 |
| 11/16/2026 | $15.81 | $15.81 | $13.56 | $14.10 | $14.10 | 211,343 |
| 11/13/2026 | $17.69 | $17.69 | $14.30 | $16.12 | $16.12 | 274,955 |
| 11/12/2026 | $18.23 | $18.92 | $17.21 | $17.50 | $17.50 | 147,421 |
| 11/11/2026 | $19.24 | $19.99 | $18.51 | $18.66 | $18.66 | 122,973 |
| 11/10/2026 | $19.73 | $20.35 | $18.76 | $18.76 | $18.76 | 132,863 |
| 11/9/2026 | $18.90 | $21.20 | $17.95 | $20.14 | $20.14 | 187,454 |
| 11/6/2026 | $18.36 | $19.00 | $17.85 | $18.73 | $18.73 | 205,562 |
| 11/5/2026 | $19.35 | $19.74 | $16.87 | $18.01 | $18.01 | 141,747 |
Analyst Price Targets
Based on 3 analysts covering CUE · as of Oct 5, 2026
Wall Street analysts forecast CUE stock price to rise 1748.7% over the next 12 months.
Consensus
Strong Buy5.00 / 5.00
Avg. Target
US$88.00
+1748.7% Upside
Current Price
US$4.76
Last close
Analyst Breakdown (3 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CUE's historical volatility
30-Day Vol
510.3%
Annualized
90-Day Vol
311.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$3.98
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$4.48 | US$0.77 – US$26.09 |
| 60 trading days | US$4.23 | US$0.35 – US$50.97 |
| 90 trading days | US$3.98 | US$0.19 – US$84.04 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Financials
- Revenue (TTM)
- $37.66M
- EBITDA
- $-97.28M
- Profit Margin
- 0.00%
- ROE (TTM)
- -1603.48%
- EPS (Diluted)
- -29.59
- Book Value
- 0.44
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About CUE.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SKYA | SkyAI, Inc. | $4.13 | +90.32% |
| CLRO | ClearOne Inc | $6.90 | +46.19% |
| AZI | Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares | $1.04 | +42.45% |
| NUR | Nuran Wireless Inc. Common Shares | $0.50 | +33.76% |
| ANPA | Rich Sparkle Holdings Limited Ordinary Shares | $1.40 | +33.33% |
| ICU | SeaStar Medical Holding Corporation | $1.04 | +33.16% |
| HIHO | Highway Holdings Limited | $1.61 | +30.89% |
| HPAI | Helport AI Limited Ordinary Shares | $0.26 | +27.23% |
Free with a Wealth Awesome account
Keep analysing CUE, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.
